+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hereditary Angioedema Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • PDF Icon


  • 70 Pages
  • November 2021
  • Region: Global
  • VPA Research
  • ID: 5464137
Hereditary Angioedema pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Hereditary Angioedema pipeline drugs and companies” presents key-decision makers with critical insights into Hereditary Angioedema pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Hereditary Angioedema pipeline Drug Snapshot, 2021

The Hereditary Angioedema pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Hereditary Angioedema. In addition to recent status, overview of drugs is included in the study. Wide range of Hereditary Angioedema drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Hereditary Angioedema drug development pipeline by phase

The Hereditary Angioedema pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Hereditary Angioedema pipeline candidates is provided in the report enables you to understand timetable developments in Hereditary Angioedema therapeutic area.

Hereditary Angioedema pipeline drug Technology, Licensing and Collaboration Details

Details of technologies used for development of Hereditary Angioedema pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Hereditary Angioedema research study. Companies looking to partner with other players are also detailed in the report.

Hereditary Angioedema- mechanism of action of pipeline candidates

Hereditary Angioedema pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Hereditary Angioedema companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Hereditary Angioedema drug administration.

Hereditary Angioedema Drugs- Preclinical and Clinical Trials

This chapter in Hereditary Angioedema preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Hereditary Angioedema product area. Preclinical and clinical trial details of pipeline candidates for Hereditary Angioedema are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Hereditary Angioedema companies and Profiles

Companies developing Hereditary Angioedema pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Hereditary Angioedema Market Developments

The report presents the recent news and developments in the Hereditary Angioedema pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the Hereditary Angioedema R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of Hereditary Angioedema pipeline drugs and clinical trials
  • Identify Hereditary Angioedema drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the Hereditary Angioedema drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the Hereditary Angioedema pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global Hereditary Angioedema pipeline news, developments and insights

Scope of the Report

  • Disease overview including Hereditary Angioedema symptoms, widely used treatment options, companies and other details are included
  • Hereditary Angioedema Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • Hereditary Angioedema pipeline drug count by phase, company and mechanism of action
  • Hereditary Angioedema companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each Hereditary Angioedema pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • Hereditary Angioedema companies including their business snapshot, business description and Hereditary Angioedema pipelines are included.
  • Recent Hereditary Angioedema market developments, pipeline news and deals are provided

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 Hereditary Angioedema Disease overview
2.2 Companies investing in Hereditary Angioedema industry
3 Hereditary Angioedema Pipeline Snapshot, 2021
3.1 Hereditary Angioedema Pipeline Drugs- Dominant phase type
3.2 Hereditary Angioedema pipeline Drugs- Leading Mechanism of Action
3.3 Hereditary Angioedema Pipeline Drugs- Widely researched Route of Administration
3.4 Hereditary Angioedema Pipeline- New Molecular Entity
3.5 Hereditary Angioedema pipeline- Companies, Universities and Institutes
4. Hereditary Angioedema Drug Profiles
4.1 Current Status of Hereditary Angioedema Drug Candidates, 2021
4.2 Hereditary Angioedema Drugs in Development- Originator/Licensor
4.3 Hereditary Angioedema Drugs in Development- Route of Administration
4.4 Hereditary Angioedema Drugs in Development- New Molecular Entity (NME)
5. Hereditary Angioedema Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. Hereditary Angioedema Companies and Universities
6.1 Leading Hereditary Angioedema companies researching in drug development
6.2 Leading Hereditary Angioedema Universities/Institutes investing in drug development
7. Hereditary Angioedema News and Deals
7.1 Recent Hereditary Angioedema Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact